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Background: The use of prescription drugs with anticholinergic properties has been
associated with multiple negative health outcomes in older people. Moreover, recent
evidence suggests that associated adverse effects may occur even decades after
stopping anticholinergic use. Despite the implicated importance of examining longitu-
dinal patterns of anticholinergic prescribing for different age groups, few such data
are available.
Methods: We performed an age-period-cohort (APC) analysis to study trends in an
aggregate measure of anticholinergic burden between the years 1990 and 2015,
utilising data from >220 000 UK Biobank participants with linked prescription data
from primary care.
Results: Anticholinergic burden in the sample increased up to 9-fold over 25 years
and was observed for both period and age effects across most classes of drugs. The
greatest increase was seen in the prescribing of antidepressants. Female sex, lower
education and greater deprivation were associated with greater anticholinergic
burden.
Conclusions: The increase in anticholinergic prescribing is mostly due to an increase
in polypharmacy and is attributable to both ageing of participants and period-related
changes in prescribing practices. Research is needed to clarify the implications of ris-
ing anticholinergic use for public health and to contextualise this rise in light of other
relevant prescribing practices.
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1 | INTRODUCTION
Medicines with anticholinergic properties – antagonists to muscarinic
receptors in the nervous system – are found among various classes
of drugs.1 Several anticholinergic drugs are listed in the American
Geriatrics Society Beers Criteria for Potentially Inappropriate Medica-
tion2 and the STOPP/START criteria for potentially inappropriate
prescribing.3 Age is the strongest predictor of polypharmacy, with the
odds of taking 10 or more medicines doubling in every decade of
life.4 Moreover, due to the age-associated decline in the ability to
metabolise drugs, older people are more sensitive to the side effects
This is a secondary investigation of an existing cohort study and therefore did not have a
Principal Investigator.
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of drugs.5 This is especially pertinent in the case of anticholinergic
compounds, which are commonly prescribed and whose side effects
are well documented.1 Anticholinergic burden in older adults is
associated with reduced physical and cognitive ability,6,7 impaired
ability to perform activities of daily living,8 increased risks of falls,9
dementia10 and mortality.11 The association with dementia has been
observed even when the anticholinergic exposure occurred decades
prior to diagnosis.10
Several tools to assess inappropriate prescribing have been
developed in the last few decades.12 Subsequently, inappropriate
prescribing in older people declined from 45.5% to 40.8% between
2006/2007 and 2009/2010 in the United States,13 and from 32.2% to
28.3% between 1996 and 2005 in the UK.14 However, older adults
remain exposed to anticholinergic drugs,15 the prevalence of which
has remained stable in the United States,16 but has increased by 3% in
the UK from 1995 to 201017 and by 12.5% in Finland from 2007 to
2017.18 While some studies have found associations between anti-
cholinergic use and demographic factors,16,17,19 these variables are
rarely examined in detail. Moreover, it is not known whether these
potential group differences persist over time.
The study of temporal changes of prescribing practices with in-
depth assessment of age-period-cohort (APC) effects necessitates
longitudinal designs. Cross-sectional studies15 or repeated cross-
sectional studies17,18 have explored the extent of anticholinergic
use in European countries,17,18 but the last year of sampling in the
UK was in 2010.17 Moreover, they either lack longitudinal data or
rely on participants from a relatively limited geographic area and
within a narrow age range. In this paper, we address those limita-
tions by using a large national sample from UK Biobank to charac-




We based our hypotheses on previous cross-sectional studies in the
UK that showed greater polypharmacy4 and anticholinergic burden17
in 2010 when compared to 1995, and increased polypharmacy in
older individuals.4 We hypothesised that anticholinergic burden
increased as a function of both period and age. Additionally, we hypo-
thesised that anticholinergic burden was higher in women and in less
educated individuals, as had been reported before.15,17
2.2 | Sample
UK Biobank is a prospective study of >500 000 participants aged
37-73 years, recruited in 22 assessment centres throughout the UK in
2006-10.20 To ensure a representative sample in the given age range,
eligible participants for the study were identified through general
practice registers and invited by post. The assessments consisted of
touch-screen questionnaires, computer-assisted interviews, measures
of physical function and the collection of blood, saliva and urine. Pri-
mary care prescriptions were available for 230 000 participants to
May 2017 for Scotland, to September 2017 for Wales and to August
2017 for England. The data were provided to UK Biobank by region-
specific data providers and include, among other information, the
dates of prescriptions, names of drugs prescribed and drug codes. The
latter include BNF codes provided by the British National Formulary,
which provides prescribing guidance on medicines (https://www.bng.
org/), Read v2- and CTV3-codes provided by the Terminology Refer-
ence Data Update Distribution (TRUD) service (https://isd.digital.nhs.
uk/), and dmd + d codes provided by the National Health Service
(NHS) (https://www.nhs.uk/). The drug code systems are used as
dictionaries for medicines.
2.3 | Assignment of anticholinergic burden and
drug class
Several resources allow for the identification of drugs with anticholin-
ergic properties and provide a score of anticholinergic potency for
each drug. These anticholinergic burden scales derive the lists of drugs
from different sources, utilise different methods to assign the scores
and validate the resulting tools in different populations and on differ-
ent outcome measures. Previous studies have compared various exis-
ting anticholinergic scales and have generally reported poor overlap
among them.21–23 For the purposes of our study, we identified
What is already known about this subject
• Anticholinergic burden has been associated with reduced
physical and cognitive ability, and an increased risk of
dementia and all-cause mortality. Extant epidemiological
studies in Europe suggest an increase in anticholinergic
prescribing over time, but focus on limited geographic
areas, utilise cross-sectional designs or focused on indi-
viduals in older age, despite the potential importance of
anticholinergic exposure throughout life.
What this study adds
• We performed an age-period-cohort analysis of changes
in anticholinergic burden in >220 000 participants from
UK Biobank, using GP electronically prescribed longitudi-
nal data from 1990 to 2015. Anticholinergic burden in
the UK has increased across several age groups and clas-
ses of prescription drugs. The increase was related to
both ageing of the underlying sample as well as period-
related changes in prescribing.
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multiple scales24–33 from a systematic review34; apart from two30,33
all had a four-point (0-3) scoring system of anticholinergic potency,
where a lower score corresponds to lower anticholinergic potency
(Supporting Information Table S1). We derived a meta-scale
(Supporting Information Table S2) by calculating the mean anticholin-
ergic burden across all nine original scales that had rated a drug. Thus,
scales that scored a drug (even if that score was zero) were included
in the computation for that drug, while scales that did not score the
drug were not. All prescriptions of medicines with ophthalmic, otic,
nasal or topical routes of administration were assigned an anticholin-
ergic score of zero, as has been done before.29,31,34,35
For prescription entries that did not list any drugs (ie, for which
the column indicating the name of the drug was blank), drug codes
were used to supplement them. A series of steps was taken to exclude
incomplete data or low number of individuals (Supporting Information
Figures S1 and S2). Drugs were classified based on the Anatomical
Therapeutic Chemical (ATC) Classification System (https://www.
whocc.no), representing (1) the anatomical target, (2) the therapeutic
subgroup, (3) the pharmacological subgroup, (4) the chemical subgroup
and (5) the chemical substance. For example, metformin (5) affects the
alimentary tract and metabolism (1), treats diabetes (2), lowers blood-
glucose (3) and is a biguanide (4). Not all classes were equally repre-
sented in the sample. To allow for comparability of frequency of
occurrence, we classified anticholinergic drugs into classes that do not
all correspond to the same level in the ATC hierarchy (see number in
parentheses): “drugs for acid disorders” (3), “analgesics” (2), “antide-
pressants” (3), “antithrombotic drugs” (2), “cardiovascular drugs” (1),
“drugs for diabetes” (2), “gastrointestinal drugs” (2), “psycholeptics”
(2), “respiratory drugs” (1) and “urological drugs” (3). A final class of
“other drugs” was constructed that contained drugs that primarily due
to their low prevalence individually contributed relatively little to the
total anticholinergic burden. These included anticonvulsants, antibi-
otics, anti-Parkinsonian drugs, corticosteroids, immunosuppressants,
anti-inflammatory drugs, muscle relaxants and anti-diarrhoeal drugs.
2.4 | Statistical approach
To enable longitudinal analyses, the original format of the data was
transformed into two different formats that reflected for each partici-
pant the monthly and yearly anticholinergic burden, respectively.
These period-based anticholinergic burden scores were calculated by
summing the anticholinergic burden of all prescriptions in that period
(Supporting Information Figure S3 and Text S1). When individual-level
data are collected longitudinally, changes can be due to age, period or
cohort effects.36 Because the three effects are colinear (age = period
cohort), they cannot all be included in a regression analysis, as holding
two terms constant keeps the third term constant as well.37 While
there have been attempts to estimate the unique contributions among
the three effects,38,39 no solution has been widely adopted. Hidden
assumptions can have a strong effect on the interpretation of the APC
effect,40 and in our analysis we make the following assumptions. First,
age is probably positively associated with anticholinergic burden due
to the positive association between polypharmacy and age.4 Second,
we assume that birth cohort does not play a role in the above associa-
tion, ie, we are only interested in whether a potential longitudinal
change in anticholinergic burden is due to the participants' age or due
to changes in prescribing practices over time. For the analysis of APC
effects, we ran three models, excluding one of the APC terms at a time
(ie, its effect was assumed to be zero). Thus, anticholinergic burden
was modelled as a function of either period and cohort (period-cohort
model), age and cohort (age-cohort model) or age and period (age-
period model). This three-model approach represents the same
process – the change in anticholinergic burden in the sample – from
three different perspectives and allows for an appraisal of possible
drivers of the observed trend. For example, assuming that the effect
of birth cohort is zero, positive effects for both period and cohort in
the period-cohort model, and a positive effect of period, but a nega-
tive effect of age in the age-period model demonstrates that anticho-
linergic burden (a) increases with time across cohorts, (b) is higher in
younger cohorts in a given period, (c) decreases with age and (d) is
higher in recent periods across age groups. This would suggest that
the anticholinergic burden increased with the time period but
decreased with age. We additionally computed the above models by
fitting separate intercepts and slopes: for the period-cohort and age-
cohort models separate intercepts and slopes for each cohort, and for
the age-period model separate intercepts and slopes for each period.
For analyses of lifestyle and demographic factors, we fitted tobit linear
models41 to average monthly anticholinergic burden, adjusting for sex,
education, physical activity, social deprivation, region, smoking, body
mass index (BMI), frequency of alcohol consumption and age at
assessment. Tobit models are models of censored regression, where
the values that fall either above or below a certain value are censored.
In our analysis, tobit models were censored from below at 0, effec-
tively simulating zero inflation. For models with random effects, we
used generalised linear mixed models (R package glmmTMB42); for all
other models, we used Tobit regression (R package censReg). Due to
the relative infrequency of anticholinergic drugs, anticholinergic bur-
den was right-skewed and models were adjusted for zero inflation.
The results are reported in unstandardised beta coefficients. The fig-
ures accompanying the analyses were generated based on the output
of these analyses. Descriptive figures depicting longitudinal changes
were based on generalised additive smoothing; whenever the latter is
the case, it is explicitly indicated. Data cleaning and statistical analyses
were performed in Python version 3.7.4 and R versions 3.4.1
and 3.6.3.
Several covariates were ascertained during or immediately prior
to the participants' recruitment to UK Biobank. These included sex
(male vs female [ref.]), education (graduate degree, no graduate degree
[ref.]), alcohol consumption (1, daily or almost daily [ref.]; 2 three or
four times a week; 3, once or twice a week; 4, one to three times a
month vs 5, only on special occasions; 6, never), smoking status
(current smoker, past smoker, never smoker [ref.]), BMI and physical
activity (strenuous, moderate, mild [ref.])43 and the Townsend Index
of Socioeconomic Deprivation44 (range 6.3-11.0). The latter is
derived from different variables available from census data and
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calculated to yield z scores. These are then summed and provide with
an index ranging from 12 to 12, with higher values indicating greater
deprivation. Region (Scotland, Wales, England [ref.]) was derived by
combining data providers so that all prescriptions issued in England,
Scotland and Wales were classified under the same category.
Each model was run in three iterations: basic models were
unadjusted; basic-adjusted models included sex, data provider,
education and socioeconomic deprivation. Data providers were spe-
cific to each prescription and available longitudinally. Sex, education
and deprivation were assumed constant (ie, treated as time-invariant
covariates) within individuals: over 90% of UK Biobank participants
reported the same educational attainment at reassessment, within-
person stability of deprivation has been reported previously.45 Fully
adjusted models were additionally controlled for smoking, alcohol
consumption frequency, BMI, and physical activity. While these
covariates were available only cross-sectionally, they are important in
health and disease. Outlier observations – for anticholinergic burden
and for polypharmacy, observations five or more interquartile ranges
beyond the median (without accounting for zero-values), for BMI
values lower than 15 and greater than 50 – were removed prior to
analysis. This resulted in the removal of at most (depending on itera-
tion) 347 297 data points (0.1% of the sample) for the data with
monthly anticholinergic burden, 42 425 data points (1.3% of the sam-
ple) for the data with yearly anticholinergic burden and 13 836 data
points (6.2% of the sample) for the individual lifestyle and
demographic data.
A sensitivity analysis was conducted that was limited to the
period from 2000 to 2015. This was done due to the relatively low
level of ascertainment in the sample before that period (Supporting
Information Figure S2).
2.5 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY, and are permanently archived in the Concise Guide to
PHARMACOLOGY 2019/20.46
3 | RESULTS
The 220 867 participants were born between 1938 and 1969
(Supporting Information Figure S4). Individuals were being added to
the database of prescriptions throughout the sampling period
(1990-2015), but the demographic structure of the sample (Table 1)
remained relatively stable over time. However, it is unclear how
demographic variables changed within individuals over time.
3.1 | Anticholinergic prescribing
Of 248 drugs on the meta-scale, 201 (81.0%) were found in the sam-
ple and constituted 25.0% of all prescriptions. A total of 199 652
participants (90.4%) were prescribed at least one anticholinergic drug
and 28 525 (13.2%) participants were prescribed anticholinergic
drugs every year during the prescribing period. Among previously
published scales, anticholinergic prescriptions constituted 2.5-23.1%
of all prescriptions (Table 2) and anticholinergic burden according to
each scale exhibited an increasing trend over time (Figure 1A).
Depending on the scale used, anticholinergic burden increased
TABLE 1 Demographic
characteristics of the sample at the time
of recruitment to UK Biobank
Variable Level Median (IQR) or n (%) Missing
Sex Female 121 286 (54.9) 0
Male 99 581 (45.1)
Education Graduate degree 69 745 (32.0) 2816
No graduate degree 148 306 (68.0)
Deprivation 2.2 (4.1) 319
Alcohol consumption Daily or almost daily 43 269 (19.6) 559
Three or four times a week 50 753 (23.0)
Once or twice a week 57 934 (26.3)
Once to three times a month 24 891 (11.3)
Only special occasions 25 274 (11.5)
Never 18 187 (8.3)
Smoking Current smoker 23 069 (10.5) 1144
Previous smoker 75 955 (34.6)
Non-smoker 120 699 (54.9)
Physical activity Strenuous 21 618 (10.6) 16 225
Moderate 129 874 (63.4)
Light 53 150 (26.0)
BMI 26.9 (5.8) 1332
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between 3- and 9-fold from 1990 to 2015. Most anticholinergic
prescriptions were for antidepressants, which accounted for 32.5%
of the total anticholinergic burden (Table 3 and Figure 1B). The
anticholinergic burden for each drug class increased with time
(Figure 1C).
3.2 | Age-period-cohort analysis
In the basic period-cohort model, anticholinergic burden was posi-
tively associated with period and negatively associated with cohort.
In the basic age-cohort model, anticholinergic burden was positively
associated with age and with cohort. In the basic age-period model,
anticholinergic burden was positively associated with age and with
period. The same trends were observed in the basic-adjusted and
fully adjusted models (Supporting Information Table S3). These
results indicate that greater anticholinergic burden relates to both
ageing and later period. That is, in a given period, older
individuals experience a higher anticholinergic burden than younger
individuals in the same period. Moreover, in recent periods,
individuals will experience a higher anticholinergic burden than
individuals of the same age did in the past. For example, the
average yearly anticholinergic burden of a 50-year-old was 2.32 in
2000, 2.92 in 2007 and 3.67 in 2015, while the average yearly anti-
cholinergic burden of a 60-year-old was 3.06 in 2000, 3.94 in 2007
and 5.12 in 2015. The trends persisted when the outcome was
the number of prescribed anticholinergic drugs (Supporting
Information Table S4). The proportion of drugs with different
anticholinergic potencies remained stable over time (Supporting
Information Figure S5). Thus, the increase in anticholinergic burden
was likely due to a general increase in anticholinergic prescribing,
rather than a relative increase in the prescribing of stronger anticho-
linergic drugs.
In the mixed-effects models, anticholinergic burden increased by
0.22 each year (SE = 0.0012, P < .001). In the period-cohort model,
earlier-born cohorts exhibited steeper slopes than later-born cohorts
(n = 32, correlation between slope and cohort r = 0.97, SE = 0.041,
P < .001; Figure 2A). In the mixed-effects age-cohort model, earlier-
born cohorts exhibited steeper slopes than later-born cohorts
(n = 32, correlation between slope and cohort r = 0.97, SE = 0.048,
P < .001). In the mixed-effects age-period model, later periods
exhibited steeper slopes than earlier periods (n = 25, correlation
between slope and period r = 0.95, SE = 0.064, P < .001).
When the change in anticholinergic burden was plotted for each
drug class separately (Supporting Information Figure S6), the same
pattern was observed for all drug classes except for drugs for acid
disorders and cardiovascular drugs. For the former, an increase in anti-
cholinergic burden over time was observed, but was similar across
periods and cohorts, suggesting an effect of age, but without a promi-
nent period effect. For cardiovascular drugs, we observed an increase
in anticholinergic burden over time and a higher anticholinergic
burden in earlier cohorts and later periods, suggesting a positive effect
of age, but a negative period effect.
When the basic models were adjusted by the addition of the total
number of prescribed drugs (Supporting Information Table S5), all
effect sizes were greatly diminished, more so by the total number of
prescribed drugs than by all other covariates combined. Furthermore,
the effect of birth cohort was reversed in the period-cohort model
and the effect of age was reversed in the age-period model. Thus, the
period effect was retained, but the effect of age was reversed when
adjusted for the number of prescribed drugs. These results possibly
indicate that whereas overall anticholinergic burden has increased
over time, and more so among older adults, anticholinergic drugs in
the latter group comprise a relatively lower proportion of overall
prescriptions when compared to younger individuals (Supporting
Information Figure S7).
TABLE 2 Comparison of the number of drugs on each anticholinergic scale, the number of drugs on each scale that were prescribed in our
sample, the percentages of all prescriptions in the sample that the drugs on the scales constituted and the increase in the mean yearly
anticholinergic burden from 1990 to 2015
Scale n drugs on the list n drugs in the sample (%) % total prescriptions 1990-2015 increase (%)
Han et al24,35 67 53 (79.1) 10.5 531
Ancelin et al25 27 21 (77.8) 2.5 464
Carnahan et al26 145 108 (74.5) 9.7 318
Chew et al27 39 33 (84.6) 11.3 697
Cancelli et al28 17 15 (88.2) 3.9 699
Rudolph et al29 69 62 (90.0) 5.9 374
Ehrt et al30 29 23 (79.3) 7.4 902
Sittironnarit et al31 49 42 (85.7) 12.5 533
Boustani et al32 (2012) 99 85 (85.9) 12.3 478
Durán et al33 180 141 (78.3) 20.7 442
Kiesel et al34 165 141 (85.5) 23.2 525
Meta-scale 248 201 (81.0) 25.0 432
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F IGURE 1 Anticholinergic burden over time based on different anticholinergic scales (A), percentage of anticholinergic burden in the sample
due to each drug class (B) and the change in anticholinergic burden over time due to each drug class (C). The plots in (A) and (C) were generated
using generalised additive smoothing
TABLE 3 Comparison of the number of anticholinergic drugs from different drug classes and their contributions to the total anticholinergic
burden







Acid disorders 1 464 542 10.3 5 0.50 5.8
Analgesics 1 426 703 10.1 12 1.48 16.5
Antidepressants 2 678 379 18.9 27 1.54 32.4
Antithrombotics 546 311 3.8 2 0.41 1.8
Cardiovascular 2 006 594 14.1 16 0.53 8.4
Diabetes 785 940 5.5 1 0.38 2.3
Gastrointestinal 220 269 1.6 9 1.18 2.0
Psycholeptic 690 894 4.9 35 1.16 6.3
Respiratory 1 499 455 10.6 33 0.88 10.3
Urological 330 314 2.3 8 2.41 6.2
Other 2 545 293 17.9 57 0.40 8.0
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3.3 | Anticholinergic burden and demographic
factors
Higher anticholinergic burden was associated with female sex, lower
educational attainment, greater deprivation, higher BMI, less frequent
alcohol consumption and lower physical activity, and was greater in
Scotland and Wales than in England (Table 4).
Examining each drug class separately, most effects remained
(Supporting Information Table S6). However, anticholinergic burden
due to antithrombotic drugs, cardiovascular drugs and drugs for
diabetes was higher in males than in females. Moreover, regional
differences in anticholinergic burden strongly depended on drug class.
Deprivation was transformed into a binary categorical variable, with
the median (2.2) across all participants defining the groups. For
F IGURE 2 APC analysis with basic mixed models with random intercepts and slopes (left) and associations between slopes and different
levels of predictors (right). (A) The period-cohort model with cohort as a random effect, (B) the age-cohort model with cohort as a random effect
and (C) the age-period model with period as the random effect
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region, sex, education and deprivation, we then plotted anticholinergic
burden as a function of period for different levels of predictor vari-
ables. Supporting Information Figure S8 illustrates the association
between the above predictors and anticholinergic burden.
3.4 | Sensitivity analyses
When the observation period was restricted to prescriptions after
1999, the trends above were again observed for all models except for
when polypharmacy was used as covariate (Supporting Information
Tables S7-10, Text S2 and Figure S9). There, period was negatively
associated with anticholinergic burden in the period cohort and in the
age-period model. Age was negatively associated with anticholinergic
burden in both the age cohort and the age-period model. Birth cohort
was positively associated with anticholinergic burden in the period-
cohort model, but negatively associated with anticholinergic burden in
the age-cohort model. Thus, when accounting for polypharmacy, the
sensitivity analysis supports an age-related decrease in anticholinergic
burden, but does not support a period-related increase in anticholiner-
gic burden.
4 | DISCUSSION
In a large longitudinal study of prescription drugs with anticholinergic
properties, we showed that the anticholinergic burden in the UK is
increasing, and older individuals continue to have the highest anticho-
linergic burden. Age-related increases in anticholinergic burden can be
explained by polypharmacy in older adults. Indeed, when accounting
for polypharmacy and period, anticholinergic burden decreases with
age, possibly demonstrating proportionate deprescribing of anticholin-
ergic drugs in older age. We also find associations between higher
anticholinergic burden and various demographic and lifestyle factors,
including female sex, less education and greater socioeconomic
deprivation.
4.1 | Anticholinergic burden over time
Anticholinergic burden increased in all APC models. Throughout
time periods and across birth cohorts, ageing was associated with
greater anticholinergic burden. Moreover, across age groups and birth
cohorts, anticholinergic burden has increased in recent years. Finally,
at a given age, later-born cohorts experienced a greater anticholinergic
burden than earlier-born cohorts, while in a given period, later-born
cohorts experienced a smaller anticholinergic burden than earlier-born
cohorts.
Because of the collinearity of age, period and cohort
(age = period cohort), they cannot all be included in a regression anal-
ysis, as holding two terms constant keeps the third term constant as
well.37 Some argue that the APC problem cannot be completely
resolved40 and that results from APC-based models should be based
on well-founded and clearly communicated assumptions. In the pre-
sent paper we assumed no cohort effects and predicted anticholiner-
gic burden to increase with ageing. Based on current knowledge on
polypharmacy and anticholinergic burden, the following conclusions
can be drawn from our results. First, due to increased multimorbidity
and polypharmacy in older individuals,4 age contributed to the trend.
When intercept and slope were modelled separately in mixed models
with random effects, cohort was negatively associated with the slope,
suggesting not only a greater anticholinergic burden, but also a more
TABLE 4 Results of the model predicting monthly anticholinergic burden as a function of deprivation, smoking, BMI, sex, education, region,
alcohol consumption, physical activity and age
Predictor Level Beta SE P
Deprivation 0.0058 2.6  104 <.001
Smoking (ref: non-smoker) Previous smoker 0.041 0.0016 <.001
Current smoker 0.072 0.0027 <.001
BMI 0.010 1.7  104 <.001
Sex Male 0.043 0.0015 <.001
Education Graduate degree 0.046 0.0016 <.001
Region (ref: England) Scotland 0.047 0.0025 <.001
Wales 0.029 0.0026 <.001
Alcohol consumption (ref: daily or almost daily consumption) Three or four times a week 0.004 0.0022 <.001
Once or twice a week 0.014 0.0022 <.001
Once to thrice a month 0.032 0.0028 <.001
Special occasions only 0.066 0.0029 <.001
Never 0.102 0.0033 <.001
Physical activity (ref: mild or no physical activity) Moderate 0.041 0.0018 <.001
Strenuous 0.072 0.0028 <.001
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rapid accumulation of burden in older individuals. Second, as previ-
ously reported,4 individuals are now being prescribed more drugs than
in the past. The increase in anticholinergic burden could be caused by
a new generation of patients who either demand more or who are
diagnosed with more maladies. Alternatively, the increase could be
related to changes in prescribing practices due to societal changes or
changes in medical training. Regardless of the underlying causes, peo-
ple in the UK are being increasingly prescribed anticholinergic drugs.
The increases in anticholinergic burden could be related to an
increase in general polypharmacy and not an increase in specifically
anticholinergic prescribing. Indeed, when the models were adjusted
for the number of prescriptions, the changes in anticholinergic burden
were greatly diminished. Furthermore, earlier-born individuals
exhibited a lower anticholinergic burden across periods and across
age groups than those born later. Moreover, across age groups, anti-
cholinergic burden was higher in later periods than in earlier periods.
While correcting for polypharmacy had no effect on the trend of the
age-cohort model, it changed the direction of birth cohort and age in
the period-cohort model and the age-period model, respectively.
Later-born individuals exhibited a higher anticholinergic burden, and
this burden was positively associated with period, but negatively asso-
ciated with age. The failure to exactly replicate these results when the
period was restricted to 2000-2015 indicates that the relationship
between polypharmacy and anticholinergic burden is complex and
warrants more detailed study. While the results indicate that medical
practitioners have been mitigating the increase in polypharmacy by
deprescribing anticholinergic drugs in older people, this group never-
theless experienced the highest burden. Furthermore, older people
experienced a greater anticholinergic burden in 2015 than at any
point in the preceding 25 years.
4.2 | Demographic- and lifestyle factors
Anticholinergic use has been linked with some demographic and life-
style factors.16,17,19 In our study, female sex, lower education, higher
socioeconomic deprivation, higher BMI, lower frequency of alcohol
consumption, lower physical activity and being prescribed in Scotland
or Wales (compared to England) were associated with a higher anti-
cholinergic burden. Certain groups do require a greater number of
medications but medical professionals may prescribe more to certain
groups, independent of underlying medical conditions.
Interestingly, greater alcohol consumption was associated with
decreased anticholinergic burden. Individuals who take many medica-
tions may reduce their alcohol consumption to reduce the risk of drug
interactions or to reduce the impact of existing disease.
4.3 | Strengths and limitations
The present study used a very large, well-characterised sample and
utilised primary care electronic prescription data over a wide period.
However, we recognise several limitations. First, while visual
inspection of anticholinergic burden across different scales did reveal
a common upward trend, our newly computed meta-scale was not
previously validated and estimates a higher anticholinergic burden
than most other scales. Second, we did not include longitudinal data
on over-the-counter drugs and dietary supplements. Considering the
availability in the UK of over-the-counter anticholinergic medicines,
especially histamines, the computed anticholinergic burden was likely
an underestimate across all scales. Third, while our assumption that
topical, ophthalmic, otic and nasal drugs do not have anticholinergic
effects is common in the literature,29,31,34,35 we are not aware of con-
clusive evidence to support it. Fourth, estimates of prevalence and
statistical inferences are dependent on the underlying sample and UK
Biobank is not representative of the UK population. On average, par-
ticipants in the study are less likely to be obese, to smoke, have fewer
health conditions and live in socioeconomically less deprived areas.47
Thus, differences in anticholinergic burden and period-dependent
disparities are possibly greater in real populations. Fifth, our analysis
of the effects of demographic and lifestyle factors on anticholinergic
burden assessed the correlation between the average value of a met-
ric that changes with time (anticholinergic burden) and cross-sectional
data (eg, BMI, smoking, alcohol consumption and physical activity),
which was ascertained towards the end of the period in question
when participants were of different ages. We also modelled depriva-
tion and educational attainment as time-invariant covariates. Thus,
our results cannot clarify the exact nature of potential temporal
relationships. Finally, we did not have data on the oldest people, who
represent the group most at risk of anticholinergic effects.
5 | CONCLUSION AND FUTURE
DIRECTIONS
Prescribing drugs involves balancing their medicinal value with poten-
tial harms. Moreover, exhaustive longitudinal studies are required to
fully determine all their effects. However, besides well-documented
side effects,48 exposure has been linked to an increased frequency of
falls,9 reduced physical, cognitive and functional ability,6–8 and
increased risks of dementia10 and all-cause mortality.11 Thus, anticho-
linergic drugs ought to be prescribed sparingly and the use of alterna-
tives strongly considered. An understanding of temporal prescribing
trends in a population may help to guide prescribing and stimulate fur-
ther research. Our work represents an overview and future studies
should describe prescribing trends and their relationship to age
groups, and demographic and lifestyle characteristics in greater detail.
There is also evidence of differences between drug classes in the
association between anticholinergic burden and health outcomes.10
Identifying distinct anticholinergic trends for individual drug classes
for different groups could help to further improve prescribing guide-
lines. Additionally, future work should attempt to identify the causes
for the increase in anticholinergic prescribing, and more precisely
quantify the potential implications for important life outcomes, includ-
ing brain and cognitive health, and dementia. Finally, decreases in
potentially inappropriate prescribing have been reported even when
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the same population experienced increases in polypharmacy and in
anticholinergic use.49 Thus, increases in anticholinergic burden should
not be considered in isolation, but in the context of other prescribing
practices.
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